If 1,5-AG levels were to be lower, this suggest that indeed remogliflozin could be a better gliflozin to prescribe for the SGLT2-therapy that is now used to treat neutropenia in GSD1b and G6PC3-deficient patients [3, 4, 14–17, 47]. The gene discussed is SLC5A2; the disease is Decreased total neutrophil count.